Zacks Investment Research
22 Jun 2026, 13:55 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Surgery Partners (SGRY) has demonstrated strong price momentum with a 26.6% gain over the last 12 weeks and an 8.6% increase over the last four weeks. — Consistent price appreciation and positive momentum scores typically attract further retail and trend-following buying pressure.
+0.30Surgery Partners (SGRY) possesses a high beta of 1.96, indicating it is significantly more volatile than the broader market. — High beta increases the risk profile of the asset, making it more susceptible to sharp declines during market downturns.
-0.10Which stocks this story touches
The article explicitly identifies the stock as a 'great candidate' for investment based on its positive momentum and attractive pricing.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
